Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0LNACX
ADC Name
1B-3R ADC
Synonyms
1B3R; 1B 3R
   Click to Show/Hide
Drug Status
Investigative
Indication
In total 1 Indication(s)
Colorectal cancer [ICD11:2B91]
Investigative
Antibody Name
Undisclosed
Antigen Name
Lactosylceramide 4-alpha-galactosyltransferase (A4GALT)
  Antigen Info 
Payload Name
Shiga toxin B subunit (StxB)
  Payload Info 
Therapeutic Target
Ribosome (RB)
  Target Info 
Linker Name
Undisclosed
Conjugate Type
Sortase A-catalyzed site-specific enzymatic ligation.
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 57.11
%
Colorectal cancer cells
Colorectal cancer
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 57.11% (Day 12)
Method Description
The inhibitory activity of 1B-3R conjugate against cancer cell growth was evaluated in various human cancer cell lines in vivo.
In Vivo Model Colorectal cancer CDX model
In Vitro Model Colorectal cancer Colorectal cancer cells Homo sapiens
References
Ref 1 Repurposing the Pentameric B-Subunit of Shiga Toxin for Gb3-Targeted Immunotherapy of Colorectal Cancer by Rhamnose Conjugation. J Pharm Sci. 2022 Oct;111(10):2719-2729.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.